# Nuvalent, Inc. (NUVL) — merger [completed]
Source: sec.gov · situation sit_98d3e84eed5ca7056068 · public 3053608866129882301 · retrieved 2026-08-20T13:52:31.971Z

## Overview
Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.

## Key dates
- Announced 2026-06-24 · Completed 2026-07-15

## Timeline
- 2026-06-24 · SC 14D9 (0001193125-26-280275): SC 14D9 - Nuvalent, Inc. — *Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.* Rule 14d-10(d) Matters The Merger Agreement provides that, prior to the Acceptance Time, the Compensation Committee will take all such actions as may be required to approve, as an employment compensation, severance or other employee benefit arrangement in accordance with Rule 14-10(d)(2) under the Exchange Act and the instructions thereto, certain compensation actions taken after January 1, 2026 and prior to the Acceptance Time that have not already been so approved. (b) Arrangements with Purchaser, Parent and Ultimate Parent. Merger Agreement On June 9, 2026, the Company, Parent, Purchaser, and, solely for purposes of Section 9.14 therein, Ultimate Parent entered into the Merger Agreement.
  https://www.sec.gov/Archives/edgar/data/1861560/0001193125-26-280275.txt
- 2026-07-07 · SC 14D9/A (0001193125-26-297541): SC 14D9/A - Nuvalent, Inc. — *Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.*
  https://www.sec.gov/Archives/edgar/data/1861560/0001193125-26-297541.txt
- 2026-07-10 · SC 14D9/A (0001193125-26-300297): SC 14D9/A - Nuvalent, Inc. — *Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.*
  https://www.sec.gov/Archives/edgar/data/1861560/0001193125-26-300297.txt
- 2026-07-15 · SC 14D9/A (0001193125-26-304120): SC 14D9/A - Nuvalent, Inc. — *Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.*
  https://www.sec.gov/Archives/edgar/data/1861560/0001193125-26-304120.txt

## Citations
- 0001193125-26-280275 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526280275
- 0001193125-26-297541 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526297541
- 0001193125-26-300297 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526300297
- 0001193125-26-304120 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526304120